ClinicalTrials.gg
SuspendedNCT01463215Updated Feb 15, 2013

Clinical Trial of Ambroxol in Patients With Type I Gaucher Disease

A Phase 1/2 interventional study of Ambroxol in Type I Gaucher Disease, sponsored by Exsar Corporation. Suspended at 1 site in United States. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2013-02-15.

Sponsored by Exsar Corporation · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 92 studies in Gaucher Disease with a site in United States — 20 open to participants now, 27 under way, 2 of them phase 3. Gaucher Disease · United States.

Planned enrollment
31st of 51
20 · median 30
Started
2012
with 2 others
Phase 1/2
6 of 92
none open now
Registered
41st of 92
by date

Among the 92 studies in Gaucher Disease with a site in United States, this one is the 31st largest by planned enrollment of the 51 interventional ones that give a count, is one of 3 that started in 2012, is one of 6 in phase 1/2, and was the 41st registered.

Gaucher Disease

177 studies on the registry are indexed under Gaucher Disease; 41 are open to participants now.

Browse Gaucher Disease studies →

Open to participants now

20 of the 92 studies in Gaucher Disease with a site in United States are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 26 Gaucher Disease studies recruiting now, 11 (42%) set no upper age limit and 11 (42%) stop at 75 or younger; 15 take children under 18; 4 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 92 studies in Gaucher Disease with a site in United States, or all of them as a file.
02

Study summary

Ambroxol is expected to improve the signs and symptoms of patients with Type I Gaucher Disease.

Read the detailed description

This is an Open-Label, Dose Escalation with 2 Dose Levels, Proof-of-Concept Clinical Trial of Ambroxol for the Treatment of Patients with Type I Gaucher Disease.

This study is a randomized clinical trial involving 20 evaluable patients affected with Type 1 Gaucher disease who are responsive to Ambroxol in vitro. There are 2 treatment groups, involving 2 dose levels of Ambroxol (187.5 and 225 mg/day), given once daily PO for 2 months in both groups. The 187.5-mg/day dose level will be tested first. If there are no significant adverse events, defined as >Grade 3 toxicity according to the latest version of the National Cancer Institute (NCI) Common Toxicity Criteria (CTC), the 225-mg/day dose level will be tested.

03

Conditions studied

  • Type I Gaucher Disease

Browse trials for

Keywords

  • Ambroxol
  • Type I Gaucher Disease
04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Biochemically and genetically confirmed diagnosis of Gaucher disease caused by β-glucocerebrosidase deficiency resulting from mutations in the GBA genes, which have been shown to respond to Ambroxol according to in vitro screening assay.
  • Must be 16 years of age or older at the time of study initiation.
  • With an intact, enlarged spleen.
  • A level of at least 10 g/L.
  • Able to understand and cooperate with the requirements of the study protocol.
  • Mentally competent, have ability to understand and willingness to sign the form.
  • Able to travel to a participating study site.
  • Women of must use accepted methods, and must have a negative serum or urine pregnancy test within one week prior to treatment initiation. An additional pregnancy test is to be performed, and results obtained, prior to administration of the first dose of Ambroxol.
  • Fertile men must practice effective contraceptive methods during the study period, unless documentation of infertility exists.
  • Body weight >40 kg (88 lbs).

Exclusion criteria

Exclusion Criteria:

  • Receipt of any form of glucocerebrosidase \<\<4 weeks prior study initiation.
  • Total splenectomy.
  • Serious medical illness, significant cardiac disease, chronic bronchitis, emphysema, and cystic fibrosis, as well as disorders causing ventilation perfusion mismatch.
  • Substance abuse.
  • Any complex disease that may confound treatment assessment.
  • Pregnant women, or women of not using reliable means of .
  • Lactating females because of the potential for adverse reactions in nursing infants.
  • Fertile men unwilling to practice contraceptive methods during the study period.
  • Unwilling or unable to follow protocol requirements.
  • Known reactions, intolerance or adverse reactions to Ambroxol or to the inactive ingredients.
  • Evidence of systemic infection, or serious infection within the past month.
  • Known to have infection.
  • Known to have or .
  • Patients with a history of convulsive disorders.
  • Patients receiving any other treatment for any indication within the past 4 weeks prior to initiation of Ambroxol treatment.
  • A history of cancer of any type.
  • Patients who have received immunotherapy of any type within the past 4 weeks prior to study initiation.
  • Any condition or abnormality which may, in the opinion of the investigator, compromise the safety of patients.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Ambroxol

    Ambroxol at a dose level of 187.5 or 225 mg/day will be given once daily by mouth for 2 months.

    Drug: Ambroxol

Interventions

  • Ambroxol at a dose level of 187.5 or 225 mg/day will be given once daily by mouth for 2 months.

    Also known as: Mucosolvon®

06

What researchers measure

Primary outcomes

  1. Safety assessment based on potential changes in physical exam, vital signs, ECG, adverse event query, and clinical lab results, when compared to baseline values.

    Safety will be based on physical exam, vital signs, ECG, adverse event query, and clinical pathology (includes chemistry, hematology and coagulation), asessed at baseline and approximately biweekly during the study.

    Time frame: Safety will be assessed at baseline and biweekly for 2 months.

Secondary outcomes

  1. efficacy based on biomarker (glucocerebrosidase activities), lab results, as well as hepatic and splenic volumes from imaging scans.

    Efficacy is based on biomarker (glucocerebrosidase activities), phenotypes according to specific lab results (acid phosphatase, angiotensin-converting enzyme, serum bilirubin, hemoglobin, platelet counts, peripheral blood leukocyte counts, serum iron, clotting time, etc.), as well as hepatic and splenic volumes.

    Time frame: Biomarker, lab results (phenotype), as well as hepatic and spenic volumes will be assessed at baseline and after 2 months of treatment, and lab results (phenotypes) will also be assessed biweekly during the 2-month treatment period.

07

Study locations

1 site
  • ExSAR Corporation
    Monmouth Junction, New Jersey 08852, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2012, a primary completion of Dec 2014 and a completion of Aug 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 27, 2011
First posted
Nov 1, 2011
Start
Dec 2012
Primary completionEst.
Dec 2014
CompletionEst.
Aug 2015
Last update
Feb 15, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 15, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01463215
Lead sponsor
Exsar Corporation
Responsible party
Sponsor
First posted
Nov 1, 2011
Start date
Dec 2012
Primary completion
Dec 2014 (estimated)
Completion
Aug 2015 (estimated)
Last update
Feb 15, 2013

Study contacts

Robert Johnston
study chair · Exsar Corporation

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is suspended, as verified in Feb 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ambroxol

Start the discussion